Dantrolene

Dantrolene

SCHEMBL40893

O=C1CN(/N=C/c2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)N1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

RYR1RYR3

The experimentally established mechanism targets of Dantrolene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 1.00
MEN1 O00255 7/20 1.00
KMT2A Q03164 7/20 1.00
LMNA P02545 5/20 1.00
TDP1 Q9NUW8 3/20 1.00
CYP1A2 P05177 3/20 1.00
CISD1 Q9NZ45 2/20 1.00
CYP3A4 P08684 2/20 1.00
ABCB11 O95342 1/20 1.00
ADORA1 P30542 1/20 1.00
SMN1; SMN2 Q16637 3/20 0.67
KDM4E B2RXH2 1/20 0.67
ABCC4 O15439 1/20 0.67
TP53 P04637 1/20 0.67
TSHR P16473 1/20 0.67
MAOA P21397 1/20 0.67
CASP7 P55210 1/20 0.67
MDM2 Q00987 1/20 0.67
HSD17B10 Q99714 1/20 0.67
BLM P54132 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dantrolene SCHEMBL56848 1.00 MAPT (1.00) MAPTMEN1KMT2ALMNATDP1
Dantrolene SCHEMBL946529 0.99 MAPT (0.98) MAPTMEN1KMT2ALMNATDP1
Dantrolene SCHEMBL29510578 0.99 MAPT (0.98) MAPTMEN1KMT2ALMNATDP1
Dantrolene SCHEMBL2903716 0.99 MAPT (0.98) MAPTMEN1KMT2ALMNATDP1
Dantrolene SCHEMBL2903719 0.99 MAPT (0.98) MAPTMEN1KMT2ALMNATDP1
Dantrolene SCHEMBL4223149 0.99 MAPT (0.98) MAPTMEN1KMT2ALMNATDP1
Dantrolene SCHEMBL979318 0.99 MAPT (0.98) MAPTMEN1KMT2ALMNATDP1
Dantrolene SCHEMBL1074050 0.98 MAPT (0.96) MAPTMEN1KMT2ALMNATDP1
Dantrolene SCHEMBL1074048 0.98 MAPT (0.96) MAPTMEN1KMT2ALMNATDP1
Dantrolene SCHEMBL1074051 0.98 MAPT (0.96) MAPTMEN1KMT2ALMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 11270 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4741492-A2 NECROSIS INHIBITOR Linkgevity Limited (GB) 2026-05-13 EP claimed
US-12605364-B2 Methods of treating SARS-CoV-2 infections EAGLE PHARMACEUTICALS, INC. (US) 2026-04-21 US claimed
EP-4725506-A2 THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Stealth BioTherapeutics Inc. (US) 2026-04-15 EP claimed
US-12594388-B2 Device to deliver a predetermined amount of a substance to a natural orifice of the body APTARGROUP, INC. (US) 2026-04-07 US claimed
US-12588828-B2 Methods and systems for diagnosing and treating fibromyalgia KATZ ROBERT S (US) 2026-03-31 US claimed
US-12582633-B2 Methods of treating severe acute respiratory syndrome EAGLE PHARMACEUTICALS, INC. (US) 2026-03-24 US claimed
US-20260076872-A1 POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME SIO2 MEDICAL PRODUCTS LLC (US) 2026-03-19 US claimed
US-20260053804-A1 Compositions and Methods for the Restoration of Ciliary Function UNIV YALE (US) 2026-02-26 US claimed
EP-3986401-B1 THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS STEALTH BIOTHERAPEUTICS INC (US) 2026-01-28 EP claimed
EP-4648769-A2 NECROSIS INHIBITOR Linkgevity Limited (GB) 2025-11-19 EP claimed
CN-1090491-A Prevent and treat pyemic method UNIV WASHINGTON (US) 1994-08-10 CN claimed
WO-1994005287-A1 PREVENTION OR TREATMENT OF SEPSIS WITH DANTROLENE OR AZUMOLENE WASHINGTON UNIVERSITY (US) 1994-03-17 WO claimed
WO-1994003166-A1 IBUPROFEN-MUSCLE RELAXANT COMBINATIONS MERCK & CO., INC. (US) 1994-02-17 WO claimed
US-4952402-A EDIBLE TASTE-MASKED DRUGS; MICROMATRIX ACTIVE MATERIAL COATED WITH NONTOXIC POLYMER; LIQUIDS; TABLETS ELAN CORPORATION, P.L.C. (IE) 1990-08-28 US claimed
EP-0205492-A1 ANALGESIC, ANTI-INFLAMMATORY AND SKELETAL MUSCLE RELAXANT COMPOSITIONS SUNSHINE, Abraham (US) 1986-12-30 EP claimed
WO-1986003681-A1 ANALGESIC, ANTI-INFLAMMATORY AND SKELETAL MUSCLE RELAXANT COMPOSITIONS SUNSHINE ABRAHAM 1986-07-03 WO claimed
US-4543359-A Treating cardiac arrhythmias with dantrolene sodium EATON LABORATORIES, INC. (US) 1985-09-24 US claimed
EP-0147780-A2 Drug delivery device MERCK & CO. INC. (US) 1985-07-10 EP claimed
EP-0105859-A1 Treating cardiac arrhytmias Norwich Eaton Pharmaceuticals, Inc. (US) 1984-04-18 EP claimed
US-4369172-A Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose FOREST LABORATORIES INC. (US) 1983-01-18 US claimed